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Abstract: Crohn’s disease (CD) is a multifactorial disease with a genetic component and 
an observed association with genes related to the innate immune response. Polymorphisms 
in the CARD15/NOD2 gene, in addition to functional variants of the toll-like receptor-4 
(TLR4) and CD14 genes, have been associated with the development of Crohn’s disease. 
There  is  no  information  about  the  frequency  of  these  polymorphisms  in  the  Saudi 
population. We examined the frequency of the three major CARD15/NOD2 risk alleles 
(Leu1007fsinsC, Arg702Trp, and Gly908Arg) and the TLR4 (Thr399Il) polymorphism as 
well as a functional polymorphism in the promoter of the CD14–159C/T in 46 Saudi CD 
patients and 50 matched controls. Genotyping was performed by allele-specific PCR or by 
restriction  fragment  length  polymorphism  (PCR-RFLP)  analysis.  The  mutant  genotype 
frequencies of the Leu1007fsinsC, Arg702Trp and Gly908Arg in the patient group were 
6.5, 21.7 and 6.5%, respectively, compared with frequencies of 0, 4 and 2%, respectively, 
in the control group. There were 15 patients who carried the mutant alleles for all three 
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CARD15/NOD2 variants, Leu1007fsinsC, Arg702Trp and Gly908Arg, while none of the 
control candidates carried the three alleles. This genetic study provides evidence that the 
three  major  CARD15/NOD2  variant  alleles  and  the  CD14  −159C/T  polymorphism  are 
associated with Crohn’s disease (CD) susceptibility in the Saudi population; however, there 
is  no  evidence  that  the  TLR4  (Thr399Il)  or  CARD15/NOD2  polymorphisms  can  be 
considered risk factors for Crohn’s disease.  
Keywords:  inflammatory  bowel  disease;  Crohn’s  disease;  genetic  polymorphism; 
CARD15/NOD2 
 
1. Introduction 
Crohn’s disease is a chronic, nonspecific, idiopathic gastrointestinal inflammatory disease that often 
leads to fibrosis and obstructive symptoms and can affect any part of the gastrointestinal tract from the 
mouth to the anus. The etiology of Crohn’s disease has not been clearly identified. Many factors have 
been suggested, but none are proven. Possible risk factors include immunologic factors, infectious 
agents (such as bacteria, viruses or amoebae), and dietary factors (including chemicals and drugs) [1]. 
Over the last decade, major advances have occurred that contribute to the understanding of the 
genetics of Crohn’s disease (CD), including studies based on single nucleotide polymorphism (SNP) 
and candidate gene approaches and studies in mouse experimental colitis using transgenic and deletion 
(knockout)  techniques.  Genome-wide  linkage  screens  have  identified  more  than  31  genetic  loci 
containing putative inflammatory bowel disease (IBD) risk factors that could be associated with CD; 
however, estimates suggest that these 31 loci only explain approximately 20% of the heritability of 
Crohn’s disease [2]. 
The discovery of CARD15/NOD2 has focused interest on the regulation of innate immune responses 
and apoptosis. This gene, with important polymorphisms, encodes the intracellular bacterial sensor. 
The  CARD15/NOD2  gene  is  located  on  chromosome  16  and  is  expressed  mainly  in  monocytes, 
dendritic  cells,  intestinal  epithelium  and  Paneth  cells  [3].  The  CARD15/NOD2  protein  recognizes 
components of the bacterial cell wall [4], is involved in the innate immune response and leads to the 
mobilization of the intracellular nuclear factor κB (NF-κB) [5]. 
The  three  major  variants  of  CARD15/NOD2,  Gly908Arg,  Arg702Trp,  and  Leu1007fsinsC,  are 
associated with a deficit in NF-κB activation in response to bacterial components, providing a unifying 
mechanism for the major CD-associated CARD15/NOD2 variants [6]. Lesage et al. suggested that 
patients carrying two variant copies of the CARD15/NOD2 gene are at increased risk of early age and 
fibrostenotic behavior of CD [2]. 
The contribution of the CARD15/NOD2 gene to CD has been studied in different ethnic populations 
with positive associations in up to 50% of CD patients [2]. However, data from Asian countries such as 
Japan and China failed to show any significant association, and no data from the Arab world could 
support  or  deny  such  association
  [7,8].  Although  it  remains  uncertain  how  or  whether  the 
CARD15/NOD2 protein interacts with other protein families involved in the innate immune response, 
the C-terminal domain of CARD15/NOD2 comprises a leucine-rich repeat (LRR) region, which has Int. J. Mol. Sci. 2012, 13  4270 
 
 
sequence homology with a number of plant disease resistance genes in the toll and toll-like receptor 
(TLR) gene superfamilies.  
Toll-like receptor 4 (TLR4) was found to be strongly up-regulated in patients with CD, and the 
allele  299Gly  has  been  associated  with  the  risk  of  developing  IBD  and  particularly  CD  [9–11].  
The TLR4 gene is expressed mainly in macrophages, dendritic cells and endothelial cells and to a 
lesser  extent  in  the  intestinal  epithelium.  The  TLR  family  is  involved  in  the  recognition  of  
pathogen-associated  molecular  patterns  by  the  immune  system.  The  TLR4  protein  recognizes 
lipopolysaccharide (LPS) from gram-negative bacteria and binds to LPS using the extracellular LRR 
domain, which leads to intracellular activation of NF-κB [12]. 
Klein  et  al.  demonstrated  an  association  of  CD  with  a  functionally  relevant  single  nucleotide 
polymorphism  in  the  promoter  of  the  CD14  gene  (T/C  at  position  −159)  and  suggested  that  the 
interaction  of  the  CARD15/NOD2  and  CD14  polymorphisms  increases  the  risk  for  developing  
CD [13]. The human CD14 gene lies on the long arm of chromosome 5 (5q31.1), a region (IBD5) that 
has been reported to be associated with CD [14].
 Membrane-bound CD14 is expressed on monocytes 
and macrophages [15]. 
To date, there has been no study performed in Asian Arabia, in particular Saudi Arabia, to evaluate 
genetic risk factors for CD among the Arab ethnic populations despite the increasing prevalence of the 
disease.  Therefore,  we  have  investigated  the  contribution  of  the  three  common  CARD15/NOD2 
mutations, as well as TLR4 and the CD14 −159C/T gene promoter polymorphism, to the predisposition 
to CD among the Saudi population.  
2. Results and Discussion 
The  demographic  and  clinical  characteristics  of  the  CD  patients  are  shown  in  Table  1.  
The demographic characteristics of the control population were similar to those of the patients. Among 
the CD patients, 31 males and 15 females, the mean age was 30.43 ±  10.20; 50% had a history of 
surgery; and 66% had been treated with biological therapy, 28 (62%) with infliximab and 3 (6%)  
with Adalimumab.  
2.1. Frequency of CARD15/NOD2 Polymorphisms 
The genotype and allele frequencies of the three major CARD15/NOD2 polymorphisms in 46 CD 
patients  and  50  healthy  controls  are  shown  in  Table  2.  The  mutant  genotype  frequencies  of 
Leu1007fsinsC, Arg702Trp and Gly908Arg in the patient group were 6.5, 21.7 and 6.5%, respectively, 
compared  with  frequencies  of  0,  4  and  2%,  respectively,  in  the  control  group.  The  mutant  allele 
frequencies of Leu1007fsinsC, Arg702Trp and Gly908Arg in the patient group were 78.3, 60.6 and 
82.6%, respectively, compared with frequencies of 20, 26 and 28%, respectively, in the control group. 
The corresponding P values and Odd ratio (OR) and 95% confidence interval {95% CI} were as 
follows: P < 0.012, OR 5.29 (CI 2.71–10.29); P < 0.0001, OR 21.87 (CI 3.99–119.9) and P < 0.015, 
OR 21.0 (CI 1.81–243.2), respectively. The P values and OR {95% CI} for the mutant alleles were as 
follows: P < 0.0001, OR 7.71 (CI 2.87–20.71); P < 0.0001, OR 9.42 (CI 3.43–25.9) and P < 0.0001, 
OR19.0 (CI 6.20–58.21). Int. J. Mol. Sci. 2012, 13  4271 
 
 
Table 1. Distribution of Chron’s disease (CD) patients according to demographic data. 
  No.  % 
Sex      
Male   31  67.4 
Female   15  32.6 
Age    
Range   18.0–70.0 
Mean ±  SD  30.43 ±  10.20 
Smoking     
No   39  84.8 
Yes   7  15.2 
Family IBD Hx     
No   37  80.4 
Yes   9  19.6 
Complication     
No not for surgery   23  50.0 
Yes for surgery   23  50.0 
Phenotype     
Fistulizing  22  47.8 
Fibrostenotic  7  15.2 
Inflammatory  16  34.8 
Fistulizing & Fibrostenotic  1  2.2 
Presenting symptoms     
Abdominal pain  38  86.4 
Anemia  7  15.9 
Arthritis  6  13.6 
Bleeding per rectum  19  43.2 
Diarrhea  33  75.0 
Eye disease  3  6.8 
Fever  10  22.7 
Perianal Disease  16  36.4 
Skin lesions  4  9.1 
Vomiting  6  13.6 
Weight loss  24  54.5 
Medications     
5-ASA   23  51.1 
Adalimumab  3  6.7 
Budesonide  3  6.7 
Imuran  35  77.8 
Infliximab  28  62.2 
Steroid  12  26.7 
Disease extent     
Ileal  10  21.7 
Ileocolonic  27  58.7 
Colonic  9  19.6 Int. J. Mol. Sci. 2012, 13  4272 
 
 
The mutant genotype for Leu1007fsinsC was not detected in any of the controls. Only one control 
subject  carried  the  mutant  genotype  for  both  the  Arg702Trp  and  Gly908Arg  polymorphisms  of 
CARD15/NOD2. There were 15 patients who carried the mutant alleles for all three CARD15/NOD2 
variants,  Leu1007fsinsC,  Arg702Trp  and  Gly908Arg,  while  none  of  the  controls  carried  the  
three alleles. 
Table 2. CARD15/NOD2 mutant allele frequencies in Saudi Crohn’s disease (CD) patients 
and controls.  
 
Homozygous 
wild-type 
Homozygous 
mutant 
P 
Heterozygous 
mutant 
P 
Or (95% ci) 
mutant 
Or (95% ci) 
hetero 
Leu1007fsinsC               
Patients  7 (15.2%)  3 (6.5%)  0.012 *  36 (78.3%) 
<0.0001 * 
5.29 
(2.71–10.29) 
7.71 
(2.87–20.71)  Controls  30 (60.0%)  0 (0.0%)    20 (20.0%) 
Arg702Trp               
Patients  8 (17.4%)  10 (21.7%)  <0.0001 *  28 (60.6%) 
<0.0001 * 
21.87 
(3.99–119.9) 
9.42 
(3.43–25.9)  Controls  35 (70.0%)  2 (4.0%)    13 (26.0%) 
Gly908Arg               
Patients  5 (10.9%)  3 (6.5%)  0.015 *  38 (82.6%) 
<0.0001 * 
21.0 
(1.81–243.2) 
19.0 
(6.20–58.21)  Controls  35 (70.0%)  1 (2.0%)    14 (28.0%) 
* Statistically significant at P ≤ 0.05. 
2.2. Frequency of TLR4 Thr399Ile and the −159 (C/T) Polymorphism of the CD14 Gene  
Allele and genotype frequencies of TLR4 Thr399Ile and the CD14 −159C/T gene polymorphism 
are presented in Table 3. There were marginal differences in the frequencies for TLR4 Thr399Ile 
between CD patients and controls. The genotype mutant frequencies for TLR4 Thr399Ile were 8.7% 
for the patients and 8% for the controls (P < 0.495), while the allele mutant frequencies for TLR4 
Thr399Ile were 39% for the patients and 28% for the controls (P < 0.226).  
Table 3. Allele and genotype frequencies for toll-like receptor-4 (TLR4) Thr399Ile and the 
CD14 −159C/T polymorphism in Saudi CD patients. 
 
Homozygous 
wild-type 
Homozygous 
mutant 
P  Heterozygous  P 
Or (95% ci) 
mutant 
Or (95% ci) 
hetero 
TLR4 Thr399Ile               
Patients  24 (52.2%)  4 (8.7%)  0.495  18 (39.1%) 
0.226 
1.33 
(0.30–5.88) 
1.71 
(0.71–4.12)  Control  32 (64.0%)  4 (8.0%)    14 (28.0) 
CD14 −159C/T gene               
Patients  13 (28.3%)  7 (15.2%)  0.075  26 (56.5%) 
0.002 * 
3.23 
(0.86–12.09) 
4.0 
(1.61–9.93)  Control  30 (60.0%)  5 (10.0%)    15 (30.0%) 
* Statistically significant at P ≤ 0.05. 
The CD14 −159C/T gene polymorphism is significantly associated with CD. The genotype mutant 
frequencies of the CD14 −159C/T were 15% for the CD patients and 10% for the controls (P < 0.075), 
while the mutant allele frequencies of the CD14 −159C/T were 26% and 15% (P < 0.002), respectively. Int. J. Mol. Sci. 2012, 13  4273 
 
 
Table 4 shows the comparisons for different allele frequencies. The statistical analysis identified a 
significant difference between Leu1007fsinsC and TLR4 Thr399Ile (P < 0.001), Arg702Trp and TLR4 
Thr399Ile (P < 0.002) and Arg702Trp with CD14 −159C/T (P < 0.001). 
Table 4. Comparison between Leu1007fsinsC, Arg702Trp, Gly908Arg, TLR4 Thr399Ile 
and CD14 −159C/T. 
  Leu1007fsinsC  Arg702Trp  Gly908Arg  TLR4 Thr399Ile  CD14 −159C/T  
  No.  %  No.  %  No.  %  No.  %  No.  % 
Wild   7  15.2  8  17.4  5  10.9  24  52.2  13  28.3 
Mutant   3  6.5  10  21.7  3  77  4  8.7  7  15.2 
Hetero   36  78.3  28  60.9  38  26  18  39.1  26  56.5 
P1    P = 0.089  P = 0.824  P < 0.001 *  P = 0.082 
P2      P = 0.0504  P = 0.002 *  P = 0.408 
P3        P = 0.025 *  P < 0.001 * 
P4          P = 0.063 
P1: P value between Leu1007fsinsC and each other mutation; P2: P value between Arg702Trp and each other 
mutation; P3: P value between Gly908Arg and each other mutation; P4: P value between TLR4 Thr399Ile 
and CD14 −159C/T. 
Positive correlations have been determined between Arg702Trp and Gly908Arg, with a correlation 
coefficient  of  rs  =  −356  (P  =  0.008),  and  between  TLR4  Thr399Ile  and  CD14  −159C/T,  with  a 
correlation coefficient of rs = −355 (P = 0.008). 
2.3. Identification of the Most Effective Mutation among CARD15/NOD2 (Leu1007fsinsC, Arg702Trp, 
Gly908Arg), TLR4 Thr399Ile and CD14 −159C/T 
Comparing the significance of each single mutation against the other mutations studied showed that 
the CARD15/NOD2 Leu1007fsinsC was more effective than TLR4 Thr399Ile, and the difference was 
highly significant (P < 0.001); additionally, CARD15/NOD2 Arg702Trp was more effective than the 
TLR4 Thr399Ile, and the difference was highly significant (P = 0.002). The CARD15/NOD2 Gly908Arg 
was more effective than TLR4 Thr399Ile and the CD14 −159C/T mutation with significant differences 
of P = 0.025 and P < 0.001, respectively. 
2.4. Comparisons between the Two Groups (Control and Patients) According to Combinations  
of Mutations 
Analysis of the coexistence of the TLR4, CARD15/NOD2 and CD14 mutated alleles showed a 
higher frequency in patients (30.4%) than in controls (8%) (Table 5).  Int. J. Mol. Sci. 2012, 13  4274 
 
 
Table 5. Comparisons between the two groups studied according to combinations of mutations. 
  Patients  Control 
  No.  %  No.  % 
None of the mutant alleles  0  0.0  7  14.0 
CARD15/NOD2  16  34.8  20  40.0 
TLR4 Thr399Ile only  0  0.0  3  6.0 
CD14 −159C/T gene  1  2.2  1  2.0 
CARD15/NOD2/TLR4 
Thr399Ile 
4  8.7  5  10.0 
CARD15/NOD2/CD14 −159C/T  11  23.9  8  16.0 
TLR4 Thr399Ile/CD14 −159C/T  0  0.0  2  4.0 
CARD15/NOD2/TLR4 
Thr399Ile/CD14 −159C/T gene 
14  30.4  4  8.0 
2.5. Analysis of the Crohn’s Disease Susceptibility Haplotype on CARD15/NOD2 
Haplotype frequencies for the Leu1007fsinsC, Arg908Trp and Gly908Arg alleles were estimated 
for controls and patients (Table 6). A score for each haplotype (Hap-score) was calculated and P-value 
was obtained for the significance of each Hap-score. The haplotype 1-2-1, which only differed from the 
protective 1-1-1 haplotype at Arg908Trp, was significantly associated with CD (OR 4.538; P < 0.0001). 
All haplotypes containing more than one mutation were significantly associated with disease. 
Table 6. Haplotypes analysis of CARD15/NOD2 polymorphism in Crohn’s disease patients 
and controls. 
Leu1007fsinsC  Arg702Trp  Gly908Arg 
Number in 
patients/47 
Number in 
control/50 
* P-value 
* Odds 
ratio 
95% confidence 
intervals 
1  1  1  28 (59.57%)  14 (28%)  0.002  3.789  1.62–8.86 
2  1  1  30 (63.82%)  23 (46%)  0.078  2.072  0.92–4.68 
1  1  2  30 (63.8%)  36 (72%)  0.388  0.686  0.29–1.62 
1  2  1  30 (63.8%)  14 (28%)  P < 0.0001  4.538  1.93–10.69 
1  2  2  32 (68.08%)  12 (24%)  P < 0.0001  6.756  2.77–16.49 
2  1  2  29 (61.70%)  17 (34%)  0.006  3.127  1.36–7.17 
2  2  1  32 (68.08%)  3 (6%)  P < 0.0001  33.422  8.94–124.92 
2  2  2  31 (65.95%)  2 (4%)  P < 0.0001  46.50  9.99–216.42 
1, wild-type; 2, mutant; * Odds ratio of disease status of each haplotype (1-1-1 reference haplotype); 
* P-value by chi square test. 
2.6. Genotype–Phenotype Analysis of CARD15/NOD2: Univariate Analysis 
There was no association between the three variants of CARD15/NOD2 and age at diagnosis, sex, 
smoking, anatomical distribution of disease, or disease behavior at diagnosis. For more information, 
see Supplementary File. Int. J. Mol. Sci. 2012, 13  4275 
 
 
3. Experimental Section  
Blood samples from 46 patients with CD and 50 age- and sex-matched healthy individuals were 
collected at the IBD Outpatient Clinic at King Khalid University Hospital (KKUH) between May 2010 
and February 2011. The diagnosis of CD was based on standard clinical, endoscopic, radiological, and 
histological criteria [1]. Clinical and demographic characteristics were recorded, including age at diagnosis, 
gender, family history, smoking habits, disease behavior, disease location, and need for surgery.  
3.1. Ethical Approval 
This study was conducted after review and approval of the Institutional Review Board of the Ethics 
Committee at KKUH, and each patient gave written informed consent. 
3.2. Methods 
Allele-specific  polymerase  chain  reactions  (PCRs)  were  used  to  detect  TLR-4,  Thr399Ile  and 
CARD15/NOD2 polymorphisms in DNA samples extracted from 5 ml of total blood samples, All PCR 
assays  were  performed  in  a  50  μL  volume  reaction  containing  10  mmol/L  Tris-HCl,  pH  8.3,  
50 mmol/L KCl, 2 mmol/L MgCl2, 250 μmol/L dNTPs, 0.20 μmol/L concentration of each primer,  
200  ng  of  genomic  DNA  and  2.5  U  of  Taq  DNA  polymerase  (Promega).  All  cycling  conditions 
initiated with denaturation at 94 ° C for 4 min followed by 35 cycles of denaturation, annealing and 
extension which varied according to primers as shown in Table 7, all PCR reactions were followed by 
terminal extension step at 72 ° C for 5 min finally the reactions were then held at 4 ° C until analysis. 
PCR products were electrophoresed in an agarose gel and visualized by ethidium bromide staining.  
Table 7. Primers and polymerase chain reaction (PCR) conditions used for genotyping 
CARD15/NOD2, TLR4 and CD14 genes. 
Gene mutation  Primer name  Primer Sequence 5'-3'  Cycling  Expected product 
CARD15/NOD2 
cytosine insertion 
mutation 
Leu1007fsinsCW
TF,  
Leu1007fsinsCR 
(common reverse) 
CAGAAGCCCTCCTGC
AGGCCCT  
TCTTCAACCACATCC
CCATT 
35 cycles of: 
94 ° C for 45 s, 
65 ° C for 40 s, 
72 ° C for 30 s 
+ve for wild 
Leu1007fsinsCM
UTF  
Leu1007fsinsCR 
(common reverse) 
CAGAAGCCCTCCTGC
AGGCCCCT  
TCTTCAACCACATCC
CCATT 
+ve for mutant 
CARD15/NOD2 
Missense mutation 
Arg702Trp 
R702WWTF 
 
R702WR, 
(common reverse) 
ATCTGAGAAGGCCC
TGCTCC  
CCCACACTTAGCCTT
GATG 
35 cycles of: 
94 ° C for 45 s, 
53 ° C for 40 s, 
72 ° C for 30 s 
+ve for wild  
R702WMUTF 
 
R702WR, 
(common reverse) 
ATCTGAGAAGGCCC
TGCTCT  
CCCACACTTAGCCTT
GATG  
+ve for mutant Int. J. Mol. Sci. 2012, 13  4276 
 
 
Table 7. Cont. 
Gene mutation  Primer name  Primer Sequence 5'-3'  Cycling  Expected product 
CARD15/NOD2 
Gly908Arg 
Gly908Arg F 
 
Gly908Arg R 
CCCAGCTCCTCCCTC
TTC  
AAGTCTGTAATGTAA
AGCCAC  
35 cycles of: 
94 ° C for 45 s, 
53 ° C for 40 s, 
72 ° C for 30 s 
For wild 380 bp fragment 
with HhaI digest 
TLR4 Thr399Ile 
Thr399Ile FW 
 
 
Thr399Ile R 
GGTTGCTGTTCTCAA
AGTGATTTTGGGAG
AA  
CCTGAAGACTGGAG
AGTGAGTTAAATGCT  
35 cycles of: 
95 ° C for 30 s, 
55 ° C for 30 s,  
72 ° C for 30 s 
For wild 377 bp With 
HinfI restriction 
For mutant 223 bp with 
HinfI restriction 
CD14 –159C/T 
CDP-1 
 
CDP-2 
TTGGTGCCAACAGAT
GAGGTTCAC  
TTCTTTCCTACACAG
CGGCACCC  
35 cycles of: 
92 ° C for 40 s, 
62 ° C for 35 s, 
72 ° C for 50 s. 
For wild 204, 201 and 156 
bp. With HaeIII digest 
For mutant 360 and 201 
bp. With HaeIII digest 
4. Conclusions  
This study is the first to determine the prevalence of CARD15/NOD2, TLR4 and CD14 −159C/T 
gene mutations in Saudi patients with CD. This genetic study provides evidence that the three major 
CARD15/NOD2 variant alleles and the CD14 −159C/T polymorphism are associated with Crohn’s 
disease  susceptibility  in  the  Saudi;  however,  there  is  no  evidence  that  the  TLR4  (Thr399Ile) 
polymorphism is associated with Saudi CD.  
Comparison of the frequencies of the mutations (Table 4) shows that TLR4 Thr399Ile is the least 
significant contributor to CD disease compared with the other mutations. 
The three main CARD15/NOD2 mutations are well-known CD-susceptibility alleles, but the risk 
associated with the mutations at the individual and population levels remains largely indeterminate. 
The  data  presented  here  and  the  reports  from  the  literature  [16–19]  demonstrate  that  in  different 
populations, large variations are observed for the frequencies of the common mutations. In Europe, 
CARD15/NOD2 mutations (especially the Gly908Arg and Leu1007fsinsC mutations) are relatively  
rare  (2.4–7%)  in  northern  countries  including  Scotland,  Finland,  Norway,  and  Sweden.  The 
frequencies of the mutations, especially the Leu1007fsinsC mutation, are relatively high (7–11.5%) in 
Central Europe including Ireland, United Kingdom, Belgium, France, Germany, Croatia, and Hungary. 
Finally,  in  Southern  countries,  including  Spain,  Portugal,  and  Italy,  the  mutation  frequency  is 
intermediate (6–7.5%) with a lower frequency for the Leu1007fsinsC mutation [20]. In our study, the 
frequencies of the CARD15/NOD2 mutations in the control group were 0–4% (Table 2), with the 
lowest frequency for the Leu1007fsinsC mutation. 
All these data (with the exception of those for Greece, where a very high rate of Leu1007fsinsC and 
a very low rate of R702W mutations are observed) are in accord with the more general observations of 
North-South  gradients  for  genetic  polymorphisms  in  Europe  that  are  compatible  with  a  spread  
of  Neolithic  farmers  from  the  Levant  10,000  years  ago  [20].  The  low  penetrance  observed  in  
at-risk  genotypes  demonstrates  that  CARD15/NOD2  does  not  delineate  a  subgroup  of  simple  
Mendelian diseases.  Int. J. Mol. Sci. 2012, 13  4277 
 
 
Our data confirmed that CARD15/NOD2 mutations are more common in CD patients than in a the 
control Saudi population, although our data showed that these mutations were not the only CD risk 
factor and that additional genetic and/or environmental cofactors not discovered yet are required for 
disease development at the individual and population levels. 
The polymorphism in the CD14 gene has been shown to increase TNF-α production in response to 
bacterial LPS and to amplify mucosal immune responses, suggesting that CD14 may play a role in the 
etiology of CD. Previous studies showed that the polymorphism in the promoter of the human CD14 
gene was associated with CD and ulcerative colitis (UC), either alone or through interaction with 
polymorphisms  in  the  CARD15/NOD2  gene  [21].  We  have  shown  that  the  CD14  −159C/T 
polymorphism in the CD14 gene was more common in CD patients than in a control Saudi population; 
however, an association of the CD14 −159C/T polymorphism with CD in other ethnic populations was 
heterogeneous and scanty. 
The  importance  of  TLR4  polymorphisms  in  CD  is  less  clear  than  the  importance  of  the 
CARD15/NOD2 mutations. Franchimont et al. have reported a two-fold elevation in allele frequency of 
TLR4 Asp299Gly in Belgian CD patients [22]. The TL4 Thr399Ile variant was associated with UC in 
a  German  study  [23];  however,  Japanese  [24]  and  Hungarian  studies  [25]  failed  to  detect  any 
individuals displaying the mutant alleles of TLR4.  
The  three  candidate  genes  of  CD14,  CARD15/NOD2  and  TLR4,  studied  in  a  Tunisian  
population  [26],  were  not  associated  with  CD,  contrary  to  the  results  obtained  with  European  and 
American populations [10].  
These findings support our results because in our study of TLR4 polymorphisms no significant 
differences in the allele or genotype frequencies between the patient and control groups were identified. 
The small size of our samples may have contributed to these negative results.  
The coexistence of the TLR4 and CD14 mutated alleles was higher in CD patients than in healthy 
subjects, and this association with increased risk of CD in the Saudi population was significant. 
Analyzing the SNP interactions will contribute to an understanding of the phenotypic variation of 
the  disease,  but  currently,  the  results  with  CD  are  controversial.  In  fact,  some  studies  show  that  
the coexistence of mutations of the CARD15/NOD2 and TLR4 genes increases the risk of developing 
CD  [27,28]  or  is  associated  with  the  phenotype  of  the  disease,  but  these  results  have  not  
been confirmed.  
The coexistence of the TLR4, CARD15/NOD2 and CD14 mutated alleles was not the same in CD 
patients and controls (Table 5). It seems that the coexistence of the three alleles could be a major risk 
of developing CD and that they may play a role in phenotype determination.  
Haplotype  frequency  analysis  of  the  CARD15/NOD2  gene  showed  that  the  haplotype  with  the 
Arg702Trp confers the single highest genetic risk for disease. This result is in agreement with previous 
studies in a Spanish population [29]. However, this mutation was not associated to CD in Galician, 
Finnish or Scottish populations [30]. The risk for CD was much greater in the presence of more than 
one of the studied CARD15/NOD2 variants.  
The presented data suggest a need for further work and larger studies to determine other genetic and 
environmental factors influencing CD susceptibility and behavior in the Saudi population. Int. J. Mol. Sci. 2012, 13  4278 
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